425: SciSparc Secures $4.2 Million Convertible Debenture Financing, Assigns $2 Million to AutoMax Motors

SciSparc Ltd. has entered into securities purchase agreements for a $4.2 million convertible debenture offering and assigned $2 million of the proceeds to AutoMax Motors in lieu of a loan payment.

Summary

• SciSparc Ltd. has entered into securities purchase agreements with investors to sell convertible debentures totaling $4.2 million.
• The debentures are convertible into SciSparc's ordinary shares.
• The purchase price is 95% of the subscription amount.
• The debentures mature one year from the issuance date and accrue interest at 8% annually, increasing to 18% upon an event of default.
• Investors can convert the debentures into ordinary shares at the lower of (i) 110% of the volume-weighted average price (VWAP) on the trading day before closing or (ii) 95% of the lowest daily VWAP during the 20 trading days before conversion, but not below a floor price of 20% of the VWAP on the day before closing.
• Investors will receive warrants exercisable into ordinary shares, with the number of shares determined by dividing the subscription amount by 130% of the VWAP immediately before closing; the warrants are exercisable for five years.
• SciSparc's subsidiaries will guarantee the company's obligations under the debenture with one of the investors through a global guaranty agreement.
• SciSparc has agreed to provide the investor with registration rights under the Securities Act of 1933.
• SciSparc assigned $2 million of the subscription amount to AutoMax Motors in lieu of a payment under a loan agreement.
• Under the loan agreement with AutoMax, SciSparc extended a $2 million loan to AutoMax, with monthly payments of $50,000 plus 8% annual interest.
• Upon consummation of the merger between SciSparc and AutoMax, the remaining interest on the loan will be cancelled, and AutoMax will continue making monthly payments towards the remaining principal.
• The company has agreed to file a registration statement with the SEC to register the resale of the conversion shares and warrant shares.

Sentiment

Score: 6

Explanation: The announcement is neutral. While it secures funding, it also introduces debt and potential dilution. The strategic shift into the automotive sector adds uncertainty.

Positives

• SciSparc secures $4.2 million in funding through convertible debentures.
• The funding supports AutoMax's growth and business expansion.
• The merger agreement between SciSparc and AutoMax is progressing.

Negatives

• The interest rate on the debentures increases significantly to 18% upon an event of default.
• The conversion price of the debentures is subject to a floor, which could limit the investor's potential upside.
• The company is relying on exemptions from registration requirements, which could limit the liquidity of the securities.

Risks

• The company's ability to meet its obligations under the debentures and warrants.
• Potential delays in the merger with AutoMax.
• The company's reliance on exemptions from registration requirements.
• The potential for dilution of existing shareholders due to the conversion of the debentures and exercise of the warrants.
• The company's ability to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company aims to expand into the automotive sector through the acquisition of AutoMax, subject to customary closing conditions, including shareholder approvals from both companies.

Industry Context

SciSparc, a pharmaceutical company, is diversifying into the automotive sector by acquiring AutoMax Motors, indicating a strategic shift in business focus.

Comparison to Industry Standards

• Convertible debentures are a common financing tool for companies, particularly those in the biotechnology and pharmaceutical industries.
• The terms of the debentures, such as the interest rate and conversion price, are generally in line with market standards for similar transactions.
• The assignment of proceeds to AutoMax Motors is an unusual arrangement, suggesting a close relationship between the two companies.
• Comparable companies that have used convertible debentures for financing include BioLineRx Ltd. and RedHill Biopharma Ltd.

Related Party Transactions

• SciSparc is assigning $2 million of the subscription amount from the convertible debentures to AutoMax Motors in lieu of a payment under a loan agreement.
• SciSparc extended a $2 million loan to AutoMax Motors, with monthly payments of $50,000 plus 8% annual interest.
• Upon consummation of the merger between SciSparc and AutoMax, the remaining interest on the loan will be cancelled.

Stakeholder Impact

• Shareholders may experience dilution due to the conversion of the debentures and exercise of the warrants.
• The funding may support the growth of AutoMax, potentially benefiting its employees and stakeholders.
• The strategic shift into the automotive sector could impact the company's long-term prospects and value.

Next Steps

• SciSparc will issue the convertible debentures and warrants to investors.
• SciSparc will file a registration statement with the SEC to register the resale of the conversion shares and warrant shares.
• AutoMax will make monthly payments to SciSparc under the loan agreement.
• SciSparc and AutoMax will seek shareholder approvals for the merger agreement.
• SciSparc will work to resolve SEC comments on its Form F-4 registration statement.

Key Dates